# Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)

> **NCT05998993** · NA · NOT_YET_RECRUITING · sponsor: **Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo** · enrollment: 35 (estimated)

## Conditions studied

- EGF-R Positive Non-Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- EGFR Exon 19 Deletion
- EGFR Exon 21 Mutation
- EGFR G719X

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy SBRT

## Key facts

- **NCT ID:** NCT05998993
- **Lead sponsor:** Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11
- **Primary completion:** 2026-11
- **Final completion:** 2028-11
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05998993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05998993, "Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05998993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*